Propanc Biopharma, Inc. — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
Propanc Biopharma received a notice of delisting or failure to satisfy continued listing rules/standards, with a transfer of listing under review. No specific counterparties, dollar amounts, or remediation timeline are disclosed in this 8-K filing. The filing indicates a regulatory compliance issue affecting the company's exchange listing status.
Why this rating
Delisting notice is business-threatening for $2.7M market-cap company; threatens access to capital markets, investor base, and operational viability.
Extracted items
Price action (we called it negative)
before filing · preread $2.11 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.